- Achievement of Disease Control in PsA Patients Treated with ...🔍
- Clinical and Economic Benefit of Achieving Disease Control in ...🔍
- Association of achieving clinical disease control criteria and patient ...🔍
- Association Between Achievement of Clinical Disease Control and ...🔍
- Importance of quick attainment of minimal disease activity for a ...🔍
- Achievement of more stringent disease control is associated with ...🔍
- Achieving Disease Control Linked to Better Quality of Life in PsA🔍
- ab1100 achievement of increasingly stringent clinical disease ...🔍
Achievement of Disease Control in PsA Patients Treated with ...
Achievement of Disease Control in PsA Patients Treated with ...
Results: At 3 years, ~50-70% of pts remained in the studies. In SELECT-PsA 1, similar proportions of pts treated with UPA15, PBO switched to UPA15, or ADA ...
Clinical and Economic Benefit of Achieving Disease Control in ...
These data demonstrate that patients with PsA and AS with lower disease activity also had lower HCRU. Compared with patients without disease control, those with ...
Association of achieving clinical disease control criteria and patient ...
Given the negative impact of PsA on patients' lives, the analysis presented here demonstrates the importance of providing treatment strategies ...
Association Between Achievement of Clinical Disease Control and ...
Patients with PsA who achieve clinical disease control are more likely to achieve ... disease control as a treatment target.
2239: Achievement of Disease Control in PsA Patients Treated with ...
Abstract Poster Presenter(s) ... Background/Purpose: A main goal of therapy for patients (pts) with PsA is to achieve and maintain the lowest possible level of ...
Association Between Achievement of Clinical Disease Control and ...
Psoriatic arthritis (PsA) is a heterogeneous condition associated with a high disease burden and significant comorbidities. The primary ...
Importance of quick attainment of minimal disease activity for a ...
Since PsA is a heterogeneous disease, it is important to treat all its facets. Earlier and more aggressive treatment with, for example, bDMARDs might be one of ...
Achievement of more stringent disease control is associated with ...
Treatment in patients with PsA, leading to the alleviation of symptoms and improved disease control, has been shown to improve work productivity ...
Achieving Disease Control Linked to Better Quality of Life in PsA
Key clinical point: Patients with psoriatic arthritis (PsA) who achieved disease control despite having an inadequate response to ...
ab1100 achievement of increasingly stringent clinical disease ...
Conclusion Patients with active PsA who achieved increasingly stringent disease control criteria at Wk 52 reported concomitantly greater improvements in patient ...
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis
As in other inflammatory rheumatic diseases, the objective of psoriatic arthritis (PsA) treatment is the achievement of a defined target.
Disease control in patients with psoriatic arthritis in real clinical ...
When the study was designed, the PsA prevalence was estimated to be around 0.25%,4 and internal data5 estimated that 50% of PsA patients on treatment would have ...
(PDF) Association Between Achievement of Clinical Disease Control ...
Conclusion Patients with PsA who achieve clinical disease control ... patient-. reported outcomes in patients with psoriatic arthritis treated ...
Durable control of psoriatic arthritis with guselkumab across ...
Patients with active PsA receiving guselkumab demonstrated durable achievement of stringent endpoints associated with disease control across key PsA domains ...
Guselkumab Yields Durable Improvements in Psoriatic Arthritis
Guselkumab durably improved disease measures in patients with psoriatic arthritis (PsA), including disease activity and patient and ...
Early Improvement of Pain, Long-Term Disease Control, and Quality ...
Upadacitinib (15mg; UPA15), an oral JAK inhibitor, has shown to rapidly and meaningfully reduce pain in patients with active PsA and inadequate response (IR) to ...
Treat-to-target in real-life psoriatic arthritis patients: achieving ...
MDA is an attainable target in real-life. AxPsA represents a difficult-to-treat subset. Sustained MDA depends on disease features (axPsA) as well as patients' ...
post hoc analysis of a phase 3, randomized, double-blind, placebo ...
... disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab ... achieving sustained minimal disease ...
Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Similar treatment target achievement rates were observed in the subgroup with ≥ 1 extraarticular PsA manifestation (n = 126; ModDA: 66.7%, HDA: ...
How to Achieve Remission in Psoriatic Arthritis
It is treated with conventional disease-modifying antirheumatic drugs (DMARDs) and biologics. In some cases, these medications can lead to a near disappearance ...